Clinical research of thalidomide in corporation with NP in treatment of Ⅲ/Ⅳ lung cancer
10.3760/cma.j.issn.1006-9801.2009.10.005
- VernacularTitle:NP方案与沙利度胺联合治疗Ⅲ、Ⅳ期非小细胞肺癌36例
- Author:
Zhenglei SHEN
;
Cunde WANG
;
Jin LIANG
;
Qing BI
;
Runxiang YANG
- Publication Type:Journal Article
- Keywords:
Carcinoma;
non-small-cell lung;
Antineoplastic combined chemotherapy protocols;
Thalidomide
- From:
Cancer Research and Clinic
2009;21(10):663-665
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the curative effect and side effect of thalidomide incorporation with NP in treatment of Ⅲ/Ⅳ lung cancer. Methods 36 lung cancer patients were randomly divided into three groups. The patients in experimental group were treated by NP plus thalidomide while without thalidomide in the control group. The difference between the first experimental group and second group is that the above used DDP followed with lobaplatin. The beginning dose of thalidomide was 100 mg/d, increase 50 mg/d every week till 400 mg/d, maintain for at least three months. Results The first experimental group had 4 partial relief cases (34.0 %), 5 improved cases(33 %), total efficacy rate was 34.4 %(4/15), clinical benefice rate 49 %(7/ 15), and the second group was 38 %(4/11), 27 %(3/11), 38 %(4/11), 55 %(6/11). All without significant difference. Conclusion It would be valuable to do clinical research further and widespread popularization study for evaluation of Thalidomide incorporation with NP in treatment of Ⅲ/Ⅳ lung cancer.
